다우존스 지수

무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

등록

AZN

AstraZeneca (AZN)

AstraZeneca PLC

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:AZN

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/03	03:32	Business Wire	TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial	NASDAQ:AZN	AstraZeneca PLC
2024/06/02	21:05	Business Wire	IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo	NASDAQ:AZN	AstraZeneca PLC
2024/06/02	21:00	Business Wire	ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy	NASDAQ:AZN	AstraZeneca PLC
2024/05/29	05:30	GlobeNewswire Inc.	Cellectis Reports Financial Results for First Quarter 2024	NASDAQ:AZN	AstraZeneca PLC
2024/05/28	22:06	Business Wire	ダトポタマブデルクステカン、進行性非扁平上皮非小細胞肺癌患者に対する第III相TROPION-Lung01試験において、化学療法と比較して臨床的に有意な全生存期間の改善を示す	NASDAQ:AZN	AstraZeneca PLC
2024/05/28	19:15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AZN	AstraZeneca PLC
2024/05/28	05:55	Business Wire	Datopotamab-Deruxtecan zeigt in Phase-III-Studie TROPION-Lung01 klinisch signifikante Verbesserung des Gesamtüberlebens im Vergleich zur Chemotherapie bei Patienten mit fortgeschrittenem nicht squamösem, nicht kleinzelligem Lungenkrebs	NASDAQ:AZN	AstraZeneca PLC
2024/05/28	02:14	Business Wire	Le datopotamab deruxtecan a montré une survie globale cliniquement significative par rapport à la chimiothérapie chez des patients atteints d'un cancer avancé du poumon non à petites cellules et non squameux	NASDAQ:AZN	AstraZeneca PLC
2024/05/27	20:00	Business Wire	Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial	NASDAQ:AZN	AstraZeneca PLC
2024/05/24	02:52	Business Wire	AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)	NASDAQ:AZN	AstraZeneca PLC
2024/05/23	20:00	Business Wire	AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)	NASDAQ:AZN	AstraZeneca PLC
2024/05/22	20:00	Business Wire	AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024	NASDAQ:AZN	AstraZeneca PLC
2024/05/22	07:44	Business Wire	アストラゼネカ、2030年までに総収益800億ドルを達成し、2030年以降も持続的な成長を実現するという野心的な目標を設定	NASDAQ:AZN	AstraZeneca PLC
2024/05/22	00:37	Business Wire	AstraZeneca strebt für 2030 einen Gesamtumsatz von 80 Milliarden US-Dollar und ein nachhaltiges Wachstum nach 2030 an	NASDAQ:AZN	AstraZeneca PLC
2024/05/22	00:36	Business Wire	AstraZeneca prévoit de réaliser un chiffre d’affaires total de 80 milliards de dollars d’ici 2030 et d’atteindre une croissance continue après 2030	NASDAQ:AZN	AstraZeneca PLC
2024/05/21	20:18	IH Market News	CalPERS to Oppose Exxon Mobil Directors; Microsoft Unveils Copilot+ PCs with AI Focus, and More News	NASDAQ:AZN	AstraZeneca PLC
2024/05/21	19:08	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AZN	AstraZeneca PLC
2024/05/21	15:00	Business Wire	AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030	NASDAQ:AZN	AstraZeneca PLC
2024/05/20	19:32	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AZN	AstraZeneca PLC
2024/05/20	06:17	Business Wire	New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease	NASDAQ:AZN	AstraZeneca PLC
2024/05/13	20:16	IH Market News	Arm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and More	NASDAQ:AZN	AstraZeneca PLC
2024/05/06	15:00	GlobeNewswire Inc.	Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca	NASDAQ:AZN	AstraZeneca PLC
2024/05/02	20:00	Business Wire	CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial	NASDAQ:AZN	AstraZeneca PLC
2024/05/01	20:05	Business Wire	AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio	NASDAQ:AZN	AstraZeneca PLC
2024/04/29	20:00	Business Wire	ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow	NASDAQ:AZN	AstraZeneca PLC
2024/04/25	21:00	PR Newswire (US)	AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	NASDAQ:AZN	AstraZeneca PLC
2024/04/25	20:53	IH Market News	U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast	NASDAQ:AZN	AstraZeneca PLC
2024/04/25	20:52	IH Market News	Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings	NASDAQ:AZN	AstraZeneca PLC
2024/04/25	15:00	Business Wire	Q1 2024 results	NASDAQ:AZN	AstraZeneca PLC
2024/04/16	20:00	Business Wire	IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial	NASDAQ:AZN	AstraZeneca PLC

검색 관련기사 보기:NASDAQ:AZN

1 2 3 4 5 6 7 8 9 10 다음 >>

Financial Select Sector

BNP Paribas (QX)

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관